Pharmacotherapy of gestational trophoblastic disease

Bibliography

• BERKOWITZ RS, GOLDSTEIN DP:Chorionic tumors. N Engl. I Med. (1996) 335:1740–1748.
   PubMed Web of Science ®Google Scholar
• •A review of gestational trophoblastic diseases.
   Google Scholar
• HERTZ R: Interference with estrogen-induced tissue growth in the chick genital tract by a folic acid antagonist. Science (1948) 107:300–302.
   PubMedGoogle Scholar
• LI MD, HERTZ R, SPENCER DB: Effects of methotrexate therapy upon choriocarcinoma and chorioadenoma. Pro. Soc. Exp. Biol. Med. (1956) 93:361–366.
   PubMed Web of Science ®Google Scholar
• HERTZ R, LEWIS J Jr, LIPSETT MD: Five years experience with chemotherapy of metastatic choriocarcinoma and related tumors in women. Am. .1. Obstet. Cynecol. (1961) 82:631–640.
   PubMed Web of Science ®Google Scholar
• ROSS GT, GOLDSTEIN DP, HERTZ R et al.: Sequential use of methotrexate and actinomycin D in the treatment of metastatic choriocarcinoma and related trophoblastic diseases in women. Am. J. °Enter Cynecol. (1965) 93:223–229.
   PubMed Web of Science ®Google Scholar
• HAMMOND CB, HERTZ R, ROSS GT, LIPSETT MD, ODELL WD: Primarychemo-therapy for nonmetastatic gestational trophoblastic neoplasms. Am. J. °Enter Cynecol. (1967) 98:71–78.
   PubMedGoogle Scholar
• SUNG HC, WU PC, HO TH: Treatmentof choriocarcinoma and chorioadenoma destruens with 6-mercaptopurine and surgery. Chin. Med. J. Engl. (1963) 82:24–28.
   PubMedGoogle Scholar
• BAGSHAWE KD: Trophoblastic tumors. Chemotherapy and developments. Br. Med. J. (1963) 2:1303–1310.
   Google Scholar
• BREWER JI, GERBIE AB,DOLKART RE, SKOM JH, NALGE RG, TOROK EE: Chemotherapy of trophoblastic diseases. Am. J. Obstet. Cynecol. (1964) 90:566–570.
   PubMed Web of Science ®Google Scholar
• SUNG HC, WU PC, YANG HY: Re-evaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms. Am. J. Obstet. Cynecol. (1984) 150:69–73.
   PubMedGoogle Scholar
• YIM CM, WONG LC, MA HK: Clinicaltrial of bleomycin in the treatment of gestational trophoblastic disease.Cynecol. Oncol. (1979) 8:296–299.
   PubMedGoogle Scholar
• GORDON AN, KAVANAGH JJ, GERSHENSON DM et al.: Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease. Cancer (1986) 58:1407–1410.
   PubMed Web of Science ®Google Scholar
• DUBESHTER B, BERKOWITZ RS, GOLDSTEIN DP: Vinblastine, cisplatin, and bleomycin as salvage therapy forrefractory high-risk metastatic gestationaltrophoblastic disease. j. Reprod. Med. (1989) 34:189–192.
   PubMed Web of Science ®Google Scholar
• NEWLANDS ES, BAGSHAWE KD: Anti-tumor activity of the epipodophyllin derivative VP16-213 (Etoposide: NSC-141540) in gestational choriocarcinoma. Eur: J. Cancer (1980) 16:401–405.
   Google Scholar
• NEWLANDS ES: New chemotherapeuticagents in the management of gestational tropho-blastic disease. Semin. Oncol. (1885) 12:37–43.
   Google Scholar
• NEWLANDS ES: VP 16 in combinations in first-line treatment of malignant germ cell tumors and gestational choriocarcinoma. Semin. Oncol. (1982) 9:239–244.
   PubMedGoogle Scholar
• SUTTON GP, SOPER JT, BLESSING JAet al.: Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease. Am. J. Obstet. Cynecol. (1992) 167:489–493.
   Google Scholar
• AZAB M, DROZ JP, THEODORE C et al.: Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors. Cancer (1989) 64:1829–1832.
   PubMed Web of Science ®Google Scholar
• WILLEMSE PHB, AALDERS JG, BOUMA J et al.: Chemotherapy-resistant gestational trophoblastic neoplasia successfully with cisplatin, etoposide, and
   Google Scholar
• ••bleomycin. Obstet. Cynecul (1988) 71:438–440.
   Google Scholar
• GARRIS PD, GALLUP DG, MELTON K: Long-term remission of previously resistant choriocarcinoma with a combination of etoposide, ifosfamide and cisplatin. Cynecul Once]. (1995) 57:254–256.
   PubMedGoogle Scholar
• PIAMSOMBOON S, KUDELKA AP, TERMANGRUANGLERT W et al.: Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and literature review. Eur.j Cynaecul Once]. (1997) 18:453–456.
   PubMed Web of Science ®Google Scholar
• KOECHLI OR, SCHAER GN,SEVIN BU et al.: In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms.Anticancer Drugs (1995) 6:94–100.
   Google Scholar
• MARTH C, LANG T,WIDSCHWENDTER M et al.: Effects ofTaxol on choriocarcinoma cells. Am. J. Obstet. Cynecul (1995) 173:1835–1842.
   PubMedGoogle Scholar
• JONES WB, SCHNEIDER J, SHAPIRO Fet al.: Treatment of resistant gestational chorio-carcinoma with Taxol: a report of two cases. Cynecul Once]. (1996) 61:126–130.
   Google Scholar
• TERMRUNGRUANGLERT W, KUDELKA AP, PIAMSOMBOON S et al.: Remission of refractory gestational trophoblastic disease with high-dose paclitaxel. Anticancer Drugs (1996) 7:503–506.
   PubMedGoogle Scholar
• GERSHON R, SERRANO A,DELCARMEN BELLO M et al.: Response of chorio-carcinoma to paclitaxel. Case report and review of resistance. Eur: Cynaecul Oncul (1997) 18:108–110.
   Google Scholar
• LURAIN JR, CASANOVA LA, MILLER DS RADEMAKER AW: Prognostic factors in gestational trophoblastic tumors. Am. Obstet. Cynecul (1991) 164:611–616.
   PubMed Web of Science ®Google Scholar
• ••An analysis of prognostic factors andclassification schemes in gestational trophoblastic tumours.
   Google Scholar
• KOHORN El: The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int. J. Cynecul Cancer (2001) 11:73–77.
   Google Scholar
• ••Presents the latest staging system forgestational trophoblastic tumours.
   Google Scholar
• LURAIN JR, ELFSTRAND EP: Single-agent methotrexate chemotherapy for thetreatment of nonmetastatic gestational trophoblastic tumors. Am. J. Obstet. Cynecul (1995) 172:574-579.An analysis of the treatment of nonmetastatic gestational trophoblastic tumours.
   Google Scholar
• BAGSHAWE KD, WILDE CE: Infusion therapy for pelvic trophoblastic tumors. Br: J. Obstet. Cynecul (1964) 71:565–570.
   Google Scholar
• BERKOWITZ RS, GOLDSTEIN DP, BERNSTEIN MR: Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Cynecul Once]. (1986) 23:111–118.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE KD, DENT J,NEWLANDS ES et al: The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours.Br: J. Obstet. Cynecul (1989) 96:795–802.
   PubMedGoogle Scholar
• WONG LC, CHOO YC, MA HK: Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. Am. J. Obstet. Cynecul (1985) 152:59–62.
   PubMed Web of Science ®Google Scholar
• ROTMENSCH J, ROSENSHEIN N, DONEHOWER R, DILLON M, VILLAR J: Plasma methotrexate levels in patients with gestational trophoblastic neoplasia treated by two methotrexate regimens. Am. J. Obstet. Cynecul (1984) 178:730–734.
   Google Scholar
• HOMESLEY HD, BLESSING JA, SCHLAERTH J et al: Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet. Cynecul (1988) 72:413–418.
   Google Scholar
• HOFFMAN MS, FIORICA JV,GLEES ON NC et al.: A single institution experience with weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Cynecul Once]. (1996) 60:292–294.
   Google Scholar
• BERKOWITZ RS, GOLDSTEIN DP, BERNSTEIN MR: Methotrexate infusion with folinic acid in primary therapy of nonmetastatic trophoblastic tumors. Cynecul Once]. (1990) 36:56–59.
   PubMedGoogle Scholar
• GARRETT AP, GARNER EO, GOLDSTEIN DP, BERKOWITZ RS: Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors.' Reprod. Med. (2002) 47:355–362.
   PubMed Web of Science ®Google Scholar
• ELIT L, COVENS A, OSBORNE R et al.: High-dose methotrexate for gestational tropho-blastic disease. Cynecul Once]. (1994) 54:282–287.
   PubMedGoogle Scholar
• WONG LC, NGAN HYS, CHENG DKL et al.: Methotrexate infusion in low-risk gestational trophoblastic disease. Am. J. Obstet. Cynecul (2000) 183:1579–1582.
   PubMedGoogle Scholar
• SMITH EB, WEED JC Jr, TYREY L et al.:Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate folinic acid. Am. J. Obstet. Cynecul (1982) 144:88–92.
   PubMed Web of Science ®Google Scholar
• GLEESON NC, FINAN MA,FIORICA JV et al.: Nonmetastatic gestational tropho-blastic trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur: Cynecul Once]. (1993) XIV:461–465.
   Google Scholar
• HILGERS RD, HERMANN JJ, SANDEFER JC: Failure of single-dose methotrexate followed by citrovorum factor in nonmetastatic gestational trophoblastic neoplasia. Cynecul Once]. (1990) 37:412–416.
   PubMedGoogle Scholar
• MUTCH DG, SOPER JT, BAKER ME et al.: Role of computed axial tomography of the of the chest in staging patients with nonmetastatic gestational trophoblastic disease. Obstet. Cynecul (1986) 68:348–352.
   Google Scholar
• OSATHANONDH R, GOLDSTEIN DP, PASTORFIDE GB: Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer (1975) 36:863–866.
   PubMed Web of Science ®Google Scholar
• PETRILLI ES, MORROW CP:Actinomycin D toxicity in the treatment of trophoblastic disease. A comparison of the 5-day course to single-dose administration. Cynecul Once]. (1980) 9:18–22.
   Google Scholar
• KOHORN El: Decision making for chemotherapy administration in patients with low-risk gestational trophoblastic neoplasia. Int J Cynecul Cancer (1996) 6:279–285.
   Google Scholar
• TWIGGS LB: Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: cost-effective chemotherapy. Cynecul Once]. (1982) 16:190–195.
   Google Scholar
• SCHLAERTH JB, MORROW CP, NALICK RH et al.: Single-dose actinomycin D in the treatment of postmolar trophoblastic disease. Cynecul Once]. (1984) 19:53–56.
   PubMed Web of Science ®Google Scholar
• PETRILLI ES, TWIGGS LB, BLESSING JAet al.: Single-dose actinomycin D treat-ment for non-metastatic gestational trophoblastic disease. Cancer (1987) 60:2173–2176.
   Google Scholar
• SMITH JP: Chemotherapy in gynecologiccancer. Clin. °Lister Gynecol (1975) 18:113–116.
   PubMedGoogle Scholar
• ROSE PG, PIVER MS: Alternating methotrexate and dactinomycin in nonmetastatic gestational trophoblastic disease. J. Surg. Oncol (1989) 41:148–152.
   PubMed Web of Science ®Google Scholar
• LURAIN JR: Treatment of gestational trophoblastic tumors. Cirri: Treat. Options Oncol (2002) 3:113–124.
   PubMedGoogle Scholar
• ••Reviews the current treatment ofgestational trophoblastic tumours.
   Google Scholar
• DUBESHTER B, BERKOWITZ RS, GOLDSTEIN DP et al.: Management of low-risk gestational tumors. I Reprod. Med. (1991) 36:36–39.
   PubMedGoogle Scholar
• SOPER JT, CLARKE-PEARSON DL, BERCHUCK A et al: Five-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol (1994) 54:76–79.
   PubMed Web of Science ®Google Scholar
• ROBERTS JP, LURAIN JR: Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am. J. Obster Gynecol (1996) 174:1917–1924.
   PubMed Web of Science ®Google Scholar
• ••A report on the largest series of patientstreated for low-risk metastatic gestational trophoblastic tumours.
   Google Scholar
• LURAIN JR: Advances in management of high-risk gestational trophoblastic tumors. Reprod. Med. (2002) 47: 451–459.
   PubMed Web of Science ®Google Scholar
• ••Reviews the management of high-riskmetastatic disease including chemotherapy, radiation and surgery.
   Google Scholar
• LURAIN JR, BREWER JI: Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D and cyclophosphamide chemotherapy. °Lister Gynecol (1985) 65:830–834.
   Google Scholar
• BEGENT RHJ, BAGSHAWE KD: The management of high-risk choriocarcinoma Semin. Oncol (1982) 9:198–203.
   Google Scholar
• CURRY SL, BLESSING JA, DISAIA PJ et al.: A prospective randomized comparison of methotrexate, actinomycin D and chlorambucil (MAC) versus modified Bagshawe regimen in 'poor-prognosis' gestational trophoblastic disease. °Lister Gynecol (1989) 73:357–362.
   Google Scholar
• NEWLANDS ES, BAGSHAWE KD, BEGENT RJH et al.: Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumors (1979–1989). Br: J. Obster Gynecol (1991) 98:550–557.
   Google Scholar
• BOLIS G, BONAZZI C, LANDONI F et al.: EMA/CO regimen in high-risk gestational trophoblastic tumor. Gynecol Oncol (1988) 31:439–444.
   PubMed Web of Science ®Google Scholar
• SCHINK JC, SINGH DK, RADEMAKER AW, MILLER DS, LURAIN JR: Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. °Lister Gynecol (1992) 80:817–820.
   Google Scholar
• SOPER JT, EVANS AC,CLARKE-PEARSON DL et al.: Alternating weekly chemotherapy with etoposide, methotrexate, dactinomycin/ cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. °lister Gynecol (1994) 83:113–117.
   Google Scholar
• QUINN M, MURRAY J,FRIEDLANDER M et al.: EMACO in high-risk gestational trophoblatic disease; the Australian experience. Aust. N41. °Lister Gynecol (1994) 34:90–92.
   Google Scholar
• BOWER M, NEWLANDS ES,HOLDEN L et al.: EMA/CO for high-risk gestational trophoblastic results; from a cohort of 272 patients. Clin. Oncol (1997) 15:2636–2643.
   Google Scholar
• ••A summary of the latest results on the useof EMA-CO for the treatment of high-risk gestational trophoblastic disease at the Charing Cross Hospital, London, UK
   Google Scholar
• KIM SJ, BAE SN, KIM JH et al.: Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. Gynecol Oncol (1998) 71:247–253.
   PubMed Web of Science ®Google Scholar
• ••An analysis of the factors that predictpoor-prognosis for high-risk trophoblastic tumors treated with the EMA-CO regimen.
   Google Scholar
• ESCOBAR PF, BOZORGI K,FISHMAN DA, LURAIN JR: Combination chemotherapy with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA-CO) for treatment of high-risk gestational trophoblastic tumors. XP World Congress on Gestational Trophoblastic Diseases, Santa Fe, NM, USA. October 30, 2001.
   Google Scholar
• SOTO-WRIGHT V, GOLDSTEIN DP, BERNSTEIN MR et al: The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D. Gynecol Oncol (1997) 64:156–159.
   PubMedGoogle Scholar
• MATSUI H, SUZUKA K, IITSUKA Y et al.: Combination chemotherapy with methotrexate etoposide, and actinomycin Dfor high-risk gestational trophoblastic tumors. Gynecol Oncol (2000) 78:28–31.
   PubMed Web of Science ®Google Scholar
• THEODORE C, AZAB M, DROZ J-P et al.: Treatment of high-risk gestational tropho-blastic disease with chemotherapy combinations containing cisplatin and etoposide. Cancer (1989) 64:1824–1829.
   PubMed Web of Science ®Google Scholar
• BAKRI Y, BERKOWITZ RS, GOLDSTEIN DP et al: Brain metastases of gestational trophoblastic tumor. J. Reprod. Med. (1994) 39:179–182.
   PubMed Web of Science ®Google Scholar
• BAKRI YN, SUBHI J, AMER M et al.: Liver metastases of gestational trophoblastic tumor. Gynecol Oncol (1993) 48:110–113.
   PubMed Web of Science ®Google Scholar
• SURWIT EA, CHILDERS JM: High-risk metastastic gestational trophoblatic disease. A new dose-intensive, multi-agent chemotherapeutic regimen. Reprod. Med. (1991) 36:45–48.
   Google Scholar
• NEWLANDS ES, MULHOLLAND PJ, HOLDEN L et al.: Etoposide and cisplatin/etopo-side, methotrexate and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine and patients presenting with metastatic placental site trophoblastic tumors. J. Clin. Oncol (2000) 18:854–859.
   PubMed Web of Science ®Google Scholar
• ••EMA-EP chemotherapy for resistant high-risk metastatic disease and placental-site tumours.
   Google Scholar
• SMALL W Jr, LURAIN JR, SHETTY RMet al.: Gestational trophoblastic disease metastatic to the brain. Radiology (1996) 200:277–280.
   Google Scholar
• RUSTIN GJ, NEWLANDS ES, BEGENT RH et al.: Weekly alternating etoposide, methotrexate, and actinomycin D/vincristine and cylcophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. Clin. Oncol (1989) 7:900–904.
   Google Scholar
• SOPER JT, EVANS AC, RODRIGUEZ G et al.: Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. Gynecol Oncol (1995) 56:421–424.
   PubMedGoogle Scholar
• OKAMOTO T, NAWA A, NAKANISHI T et al.: Usefulness of colony-stimulating factor on neutropenia in patients with invasive mole and choriocarcinoma. Oncology (Huntingt) (1995) 52:159–162.
   Google Scholar
• COLLINS RH Jr, WHITE CS,STRINGER CA et al.: Successful treatmentof refractory gestational trophoblastic
   Google Scholar
• ••neoplasm with high-dose etoposide and cyclophosphamide. Gynecol Omni (1991) 43:317–319.
   Google Scholar
• BOZORGI K, FISHMAN DA, LURAIN JR: High-dose etoposide for resistant gestational choriocarcinoma. Presented at XP World Congress on Gestational Trophoblastic Diseases, Santa Fe, New Mexico, October 30, 2001.
   Google Scholar
• LOTZ JP, ANDRE T, DONSIMONI R et al.: High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.Cancer (1995) 75:874–885.
   PubMed Web of Science ®Google Scholar
• CIACOLONE PL, BENOS P, DONNADIO D et al.: High-dose chemotherapy with autologous bone marrow transplantation for refractory metastatic gestational trophoblastic disease. Gynecol Oncol (1995) 58:383–385.
   PubMedGoogle Scholar
• VAN BESIAN K, VERSCHRAEGEN C, MEHRA R et al.: Complete remission of re-fractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, andetoposide (ICE) and stem cell rescue. Gynecol Omni (1997) 65:366–369.
   PubMedGoogle Scholar
• GOLDSTEIN DP: Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies. Obstet. Gynecol (1974) 43:475–478.
   PubMedGoogle Scholar
• KASHIMURA Y, KASHIMURA M, SUGIMORI H et al.: Prophylactic chemotherapy for hydatidiform mole: 5 — 15 years follow-up. Cancer (1986) 58:624–629.
   PubMed Web of Science ®Google Scholar
• FASOLI M, RATTI E, FRANCESCHI S, LAVECCHIA C, PECORRELLI S, MANGIONI C: Management of gestational trophoblastic disease: results of a cooperative study. Obstet. Gynecol (1982) 60:205–208.
   PubMedGoogle Scholar
• KIM DS, MOON H, KIM KT, MOON YJ, HWANG YY: Effects of prophylactic chemo-therapy for persistent trophoblastic disease in patients with complete hydatidiform mole.Obstet. Gynecol (1986) 67:690–693.
   PubMed Web of Science ®Google Scholar
• RUSTIN GJS, BOOTH M, DENT J et al.:Pregnancy after cytotoxic chemotherapy forgestational trophoblastic tumors. Br. Med. J. (1984) 288:103–106.
   PubMedGoogle Scholar
• RUSTIN GJS, RUSTIN F, DENT J, SALT S, BAGSHAWE KD: No increase in second tumors after cytoxic chemotherapy for gestational trophoblastic tumors. N Engl. J. Med. (1983) 308:473–477.
   PubMedGoogle Scholar
• RUSTIN GJ, NEWLANDS ES, LUTZ JM et al.: Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J. Clin. Oncol (1996) 10:2769–2773.
   Google Scholar
• ••Discusses the risk of secondarymalignancies in patients treated with chemotherapy for gestational trophoblastic tumours.
   Google Scholar